Expert Recommendations in Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

Myeloma News

Race Linked to Risk of Early Death From Multiple Myeloma

Source: Myeloma – Hematology Advisor

Black, Hispanic, and Asian patients have a higher risk of early death from multiple myeloma than their White peers, according to research published in Haematologica.

Researchers also found evidence to suggest that access to care may not be responsible for this difference.

For this study, researchers evaluated 77,374 patients from the SEER database who were diagnosed with multiple myeloma during 2000-2019. The researchers evaluated early mortality, which was defined as death within 2 years of multiple myeloma diagnosis.

Continue Reading

There was an increased risk of early mortality among patients who were non-Hispanic Black (odds ratio [OR], 1.10; 95% CI, 1.04-1.15; P <.01), Hispanic (OR, 1.21; 95% CI, 1.14-1.28; P <.01), or Asian (OR, 1.16; 95% CI, 1.04-1.29; P <.01), compared to non-Hispanic White patients.

Older patients also had a higher risk of early mortality. The risk was higher in patients aged 59 to 67 years (OR, 1.31; 95% CI, 1.25-1.37; P <.01), 68 to 76 years (OR, 2.01; 95% CI, 1.92-2.10; P <.01), and 77 to 99 years (OR, 4.23; 95% CI, 4.05-4.43; P <.01), compared to patients aged 18 to 58 years.

On the other hand, there was a lower risk of early mortality among:

Women (OR, 0.89; 95% CI, 0.86-0.92; P <.01)

Patients with a median annual income of $70,000 or higher (OR, 0.81; 95% CI, 0.78-0.85; P <.01)

Patients diagnosed during 2006-2011 (vs 2000-2005; OR, 0.68; 95% CI, 0.66-0.71; P <.01)

Patients diagnosed during 2012-2017 (OR, 0.59; 95% CI, 0.56-0.61; P <.01).

Among patients in the higher income category (≥$70,000 per year), the increased likelihood of early mortality persisted in non-Hispanic Black patients (OR, 1.18; 95% CI, 1.10-1.27) and Hispanic patients (OR, 1.32; 95% CI, 1.22-1.44) but not in Asian patients (OR, 1.06; 95% CI, 0.98-1.16; P =.2).

“Our results would support the notion that the disparities between minorities and NHWs [non-Hispanic Whites] are beyond that of access to care tied to socioeconomic status,” the researchers concluded. “There may be further merit in evaluating biologic differences.”

Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.

Wei JX, Shastri A, Sica RA, et al. Impact of race and ethnicity on early mortality in multiple myeloma: A SEER analysis. Haematologica. Published online October 26, 2023. doi:10.3324/haematol.2023.283304

Read More

Early Relapse Within 18 Months Is Prognostic in Multiple Myeloma

Source: Myeloma – Hematology Advisor

Early relapse after initial therapy, defined as 18 months (ER18), was strongly prognostic for early progression and higher risk among patients with multiple myeloma (MM), according to the results of an analysis of data from the National Longitudinal Cohort of Hematological Diseases in China cohort. The results of the study were published in the journal Cancer.

Although early relapse has been known to be prognostic for worse outcomes among patients with MM, the timing of relapse varies between studies. The aim of this study was to define the optimal duration for prognostication.

The study evaluated data from 629 patients with newly-diagnosed MM. Of these patients, 19.4% developed ER18, who were more likely to have anemia (P <.001), thrombocytopenia (P =.004) and high-risk cytogenetics (P ≤.007).

Continue Reading

The ER18 cohort demonstrated more aggressive biologic features and were less likely to respond to initial treatment (P <.001). The median overall survival (OS) was 28.9 months, which was significantly shorter than the xx months of patients who did not relapse within 18 months.

OS was significantly shorter in the ER18 cohort compared with patients who did not relapse within 18 months, with a median of 28.9 months compared with 85.6 months, respectively (P <.001). The risk of death was higher in the ER18 group (hazard ratio [HR], 6.342; 95% CI, 4.603-8.739; P <.001).

In a multivariate analysis, ER18 was associated with a significant risk of death (HR, 4.467; 95% CI, 3.012-6.625; P <.001), which was greater than that of ISS stage, lactate dehydrogenase level at diagnosis, thrombocytopenia, or high-risk cytogenetics (HR range, 1.598-2.071).

The study also evaluated the effect of incorporating ER18 as a complement to the R-ISS model and developed a second-state model based on the reorganization of the OS groups classified by R-ISS staging and ER18.

The concordance index of this model on adjusted OS was 0.726. The model also identified an ultra-high-risk subgroup that demonstrated a median OS of 8.9 months after first relapse. “Collectively, this study concludes that ER18 is a simple and dynamic prognostic predictor in MM,” the authors wrote in their report.

Disclosures: Some of the study authors declared affiliations with biotech, pharmaceutical, or device companies. Please see the original reference for a full list of disclosures.

Yan W, Xu J, Fan H, et al. Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma. Cancer. Published online October 17, 2023. doi: 10.1002/cncr.35056

Read More

Recent Publications

CAR T-Cell Therapy in Multiple Myeloma: Mission Accomplished?

Blood. 2023 Nov 30:blood.2023021221. doi: 10.1182/blood.2023021221. Online ahead of print. ABSTRACT BCMA-CAR T-cells are the most potent treatment against multiple myeloma. Here, we review the increasing body of clinical and correlative pre-clinical data that support their inclusion into...

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.